118 related articles for article (PubMed ID: 32571117)
1. Short-term treatment with imetelstat sensitizes hematopoietic malignant cells to a genotoxic agent via suppression of the telomerase-mediated DNA repair process.
Hidaka D; Onozawa M; Miyashita N; Yokoyama S; Nakagawa M; Hashimoto D; Teshima T
Leuk Lymphoma; 2020 Nov; 61(11):2722-2732. PubMed ID: 32571117
[TBL] [Abstract][Full Text] [Related]
2. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
[TBL] [Abstract][Full Text] [Related]
3. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
Biochim Biophys Acta; 2012 Dec; 1823(12):2130-5. PubMed ID: 22906540
[TBL] [Abstract][Full Text] [Related]
4. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
Hu Y; Bobb D; Lu Y; He J; Dome JS
Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
[TBL] [Abstract][Full Text] [Related]
5. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
Hu Y; Bobb D; He J; Hill DA; Dome JS
Cancer Biol Ther; 2015; 16(6):949-57. PubMed ID: 25920748
[TBL] [Abstract][Full Text] [Related]
6. Transient Telomerase Inhibition with Imetelstat Impacts DNA Damage Signals and Cell-Cycle Kinetics.
Thompson CAH; Gu A; Yang SY; Mathew V; Fleisig HB; Wong JMY
Mol Cancer Res; 2018 Aug; 16(8):1215-1225. PubMed ID: 29759988
[TBL] [Abstract][Full Text] [Related]
7. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
[TBL] [Abstract][Full Text] [Related]
8. Characterization of
Carloni LE; Wechselberger R; De Vijlder T
Nucleic Acid Ther; 2021 Oct; 31(5):341-350. PubMed ID: 34018844
[TBL] [Abstract][Full Text] [Related]
9. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms.
Brennan SK; Wang Q; Tressler R; Harley C; Go N; Bassett E; Huff CA; Jones RJ; Matsui W
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824134
[TBL] [Abstract][Full Text] [Related]
10. Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms.
Uziel O; Beery E; Dronichev V; Samocha K; Gryaznov S; Weiss L; Slavin S; Kushnir M; Nordenberg Y; Rabinowitz C; Rinkevich B; Zehavi T; Lahav M
PLoS One; 2010 Feb; 5(2):e9132. PubMed ID: 20161752
[TBL] [Abstract][Full Text] [Related]
11. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.
Marian CO; Cho SK; McEllin BM; Maher EA; Hatanpaa KJ; Madden CJ; Mickey BE; Wright WE; Shay JW; Bachoo RM
Clin Cancer Res; 2010 Jan; 16(1):154-63. PubMed ID: 20048334
[TBL] [Abstract][Full Text] [Related]
12. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses.
Masutomi K; Possemato R; Wong JM; Currier JL; Tothova Z; Manola JB; Ganesan S; Lansdorp PM; Collins K; Hahn WC
Proc Natl Acad Sci U S A; 2005 Jun; 102(23):8222-7. PubMed ID: 15928077
[TBL] [Abstract][Full Text] [Related]
13. Oligonucleotides Targeting Telomeres and Telomerase in Cancer.
Schrank Z; Khan N; Osude C; Singh S; Miller RJ; Merrick C; Mabel A; Kuckovic A; Puri N
Molecules; 2018 Sep; 23(9):. PubMed ID: 30189661
[TBL] [Abstract][Full Text] [Related]
14. Efficient inhibition of human telomerase activity by antisense oligonucleotides sensitizes cancer cells to radiotherapy.
Ji XM; Xie CH; Fang MH; Zhou FX; Zhang WJ; Zhang MS; Zhou YF
Acta Pharmacol Sin; 2006 Sep; 27(9):1185-91. PubMed ID: 16923339
[TBL] [Abstract][Full Text] [Related]
15. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
Koziel JE; Herbert BS
Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
[TBL] [Abstract][Full Text] [Related]
16. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells.
Goldkorn A; Blackburn EH
Cancer Res; 2006 Jun; 66(11):5763-71. PubMed ID: 16740715
[TBL] [Abstract][Full Text] [Related]
17. Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions.
Vasko T; Kaifie A; Stope MB; Kraus T; Ziegler P
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29143804
[TBL] [Abstract][Full Text] [Related]
18. Tianshengyuan-1 (TSY-1) regulates cellular Telomerase activity by methylation of TERT promoter.
Yu W; Qin X; Jin Y; Li Y; Santiskulvong C; Vu V; Zeng G; Zhang Z; Chow M; Rao J
Oncotarget; 2017 Jan; 8(5):7977-7988. PubMed ID: 28002788
[TBL] [Abstract][Full Text] [Related]
19. Telomere length mediates the effects of telomerase on the cellular response to genotoxic stress.
Rubio MA; Davalos AR; Campisi J
Exp Cell Res; 2004 Aug; 298(1):17-27. PubMed ID: 15242758
[TBL] [Abstract][Full Text] [Related]
20. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function.
Burger AM; Dai F; Schultes CM; Reszka AP; Moore MJ; Double JA; Neidle S
Cancer Res; 2005 Feb; 65(4):1489-96. PubMed ID: 15735037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
